<DOC>
	<DOC>NCT00793520</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of milnacipran on how the brain processes pain in patients with fibromyalgia and to assess the relationship between this effect and brain activation patterns during functional magnetic resonance imaging.</brief_summary>
	<brief_title>Effect of Milnacipran on Pain Processing and Functional Magnetic Resonance Imaging (fMRI) Activation Patterns in Patients With Fibromyalgia</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Diagnosis of fibromyalgia defined by 1990 American College of Rheumatology (ACR) criteria Visual analog pain score between 40 and 90 mm Righthand dominance Suicidal risk Substance Abuse Pulmonary dysfunction Renal impairment Active cardiac disease Autoimmune disease Uncontrolled narrowangle glaucoma Active liver disease Cancer Active peptic ulcer disease or a history of inflammatory bowel disease or celiac sprue Unstable endocrine disease Prostatic enlargement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>fibromyalgia</keyword>
	<keyword>milnacipran</keyword>
	<keyword>Forest Laboratories</keyword>
</DOC>